Clinical trial
A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT04594707 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- August 30, 2021
- Completion date
- February 10, 2023
- Enrollment
- 117 (actual)
- Sites
- 248
Conditions
As the registry lists them; a condition with its own page is linked.